Biochemical Mechanisms of Action of Hypericum LI 160 In Glial and Neuronal Cells: Inhibition Of Neurotransmitter Uptake and
Stimulation of Extracellular Signal Regulated Protein Kinase

We have investigated biochemical mechanisms that may underlie the antidepressant effects of Hypericum LI 160. We found that LI 160 inhibits uptake of serotonin and norepinephrine in cultures of rat cortical astrocytes. Observed differences in the kinetic parameters Km and Vmax as well as in the recovery of uptake after removal of Hypericum indicates that LI 160 does not affect serotonin and norepinephrine transport in the same manner. This suggests that multiple components of the extract can mediate inhibition of these neurotransmitter transporters. Hypericum LI 160 also inhibits serotonin uptake in neuronal cultures from serotonergic-rich raphe nuclei; concentration-response studies indicate LI 160 is 25 times more potent in terms of inhibition of serotonin uptake in neurons than in astrocytes. In addition, Hypericum LI 160 inhibits norepinephrine uptake in SK-N-SH cells, a human neuroblastoma cell line enriched in norepinephrine transporters. A chemical constituent of LI 160, hyperforin, is about 10 to 20 times more potent than LI 160 in inhibiting neurotransmitter uptake in astrocytes and neuronal cells; this finding is consistent with the observation that hyperforin comprises 5 % of LI 160 extracts. As several weeks are needed to achieve a clinical response with antidepressants, we have also investigated whether Hypericum LI 160 affects biochemical mechanisms that underlie long-term changes such as gene expression. We found that LI 160 stimulates a sustained activation of extracellular signal regulated protein kinase (ERK), a key component of a signal transduction pathway involved in gene expression. Taken together, our findings suggest that Hypericum LI 160 can affect rapidly-acting as well as slower-developing, long-term biochemical mechanisms related to depressive disorders.

References

• 1 Amara S G, Kuhar M J. Neurotransmitter transporters: Recent progress.  Annu Rev Neurosci. 1993;  16 73-93
• 2 Bal N, Figueras G, Vilaro M T, Sunol C, Artigas F. Antidepressant drugs inhibit a glial 5-hydroxytryptamine transporter in rat brain.  Eur J Neurosci . 1997;  9 1728-1738
• 3 Bladt S, Wagner H. Inhibition of MAO by fractions and constituents of hypericum extract.  J Geriatr Psychiatr Neurol. 1994;  7 (Suppl 1) S 57-S 59
• 4 Chatterjee S S, Bhattacharya S K, Wonnemann M, Singer A, Muller W E. Hyperforin as a possible antidepressant component of Hypericum extracts.  Life Sci. 1998;  63 499-510
• 5 Chatterjee S S, Noldner  M, Koch E, Erdelmeier C. Antidepressant activity of Hypericum perforatum and hyperforin: the neglected possibility.  Pharmacopsychiatry. 1998;  31 (Suppl) 7-15
• 6 Cott J M. In vitro receptor binding and enzyme inhibition by Hypericum perforatum extract.  Pharmacopsychiatry. 1997;  30 (Suppl) 108-112
• 7 Fuller R W, Wong D T. Serotonin uptake and serotonin uptake inhibition.  Ann NY Acad Sci . 1990;  600 68-78
• 8 Glowinski J, Axelrod J. Inhibition of uptake of tritiated-noradrenaline in the intact rat brain by imipramine and structurally related compounds.  Nature. 1964;  204 1318-1319
• 9 Graham D, Tahraoui L, Langer S Z. Effect of chronic treatment with selective monoamine oxidase inhibitors and specific 5-hydroxytryptamine uptake inhibitors on [3H]paroxetine binding to cerebral cortical membranes of the rat.  Neuropharmacol. 1987;  26 1087-1092
• 10 Harrer G, Schulz  V. Clinical investigation of the antidepressant effectiveness of hypericum.  J Geriatr Psychiatr Neurol. 1994;  7 (Suppl 1) S 6-S 8
• 11 Horn A S, Coyle J T, Snyder  S H. Catecholamine uptake by synaptosomes from rat brain. Structure-activity relationships of drugs with differential effects on dopamine and norepinephrine neurons.  Mol Pharmacol. 1971;  7 66-80
• 12 Hrdina P D. Regulation of high- and low-affinity [3H]imipramine recognition sites in rat brain by chronic treatment with antidepressants.  Eur J. Pharmacol. 1987;  138 159-168
• 13 Kuhar M J, Roth R H, Aghajanian  G K. Synaptosomes from forebrains of rats with midbrain raphe lesions: selective reduction of serotonin uptake.  J Pharmacol Exp Ther. 1972;  181 36-45
• 14 Lesch K P, Aulakh C S, Wolozin B L, Tolliver T J, Hill J L, Murphy D L. Regional brain expression of serotonin transporter mRNA and its regulation by reuptake inhibiting antidepressants.  Molec Brain Res. 1993;  17 31-35
• 15 Linde K, Ramierez G, Mulrow C D, Pauls A, Weidenhammer W, Melchart D. St. John’s wort for depression - an overview and meta-analysis of randomised clinical trials.  Brit Med J. 1996;  313 253-258
• 16 Meloche S, Seuwen K, Pages G, Pouyssegur J. Biphasic and synergistic activation of p44-mapk (ERK1) by growth factors: correlation between late phase activation and mitogenicity.  Molec Endocrinol. 1992;  6 845-854
• 17 Muller W .E, Rolli M, Schafer C, Hafner U. Effects of hypericum extract (LI 160) in biochemical models of antidepressant activity.  Pharmacopsychiatry. 1997;  30 (Suppl) 102-107
• 18 Muller W .E, Singer A, Wonnemann M, Hafner U, Rolli M, Schafer C. Hyperforin represents the neurotransmitter reuptake inhibiting constituent of Hypericum extract.  Pharmacopsychiatry. 1998;  31 (Suppl) 16-21
• 19 Neary J T. MAPK cascades in cell growth and death.  News in Physiol Sci . 1997;  12 286-293
• 20 Neary J T, Bu Y. Hypericum LI 160 inhibits uptake of serotonin and norepinephrine in astrocytes.  Brain Res. 1999;  816 358-363
• 21 Neary J T, Kang  Y, Bu Y, Yu E, Akong K, Peters  C M. Mitogenic signaling by ATP/P2Y purinergic receptors in astrocytes: involvement of a calcium-independent protein kinase C, extracellular signal regulated protein kinase pathway distinct from the phosphatidylinositol-specific phospholipase C, calcium pathway.  J Neurosci. 1999;  19 4211-4220
• 22 Ross S B, Renyi A L. Tricyclic antidepressant agents. I. Comparison of the inhibition of the uptake of 3-H-noradrenaline and 14-C-5-hydroxytryptamine in slices and crude synaptosome preparations of the midbrain-hypothalamus region of the rat brain.  Acta Pharmacol Toxicol. 1975;  36 382-394
• 23 Rudge J S, Eaton M J, Mather P, Lindsay R M, Whittemore S R. CNTF induces raphe neuronal precursors to switch from a serotonergic to a cholinergic phenotype in vitro.  Molec Cell Neurosci. 1996;  7 204-221
• 24 Schildkraut J J, Kety S S. Biogenic amines and emotion.  Science. 1967;  156 21-30
• 25 Seger R, Krebs E G. The MAPK signaling cascade.  FASEB J. 1995;  9 726-735
• 26 Shaskan E G, Snyder S H. Kinetics of serotonin accumulation into slices from rat brain: relationship to catecholamine uptake.  J Pharmacol Exp Ther. 1970;  175 404-418
• 27 Singer A, Wonnemann M, Muller W E. Hyperforin, a major antidepressant constituent of St. John’s wort, inhibits serotonin uptake by elevating free intracellular Na^{+ 1}.  J Pharmacol Exp Ther. 1999;  290 1363-1368
• 28 Snyder S H. Putative neurotransmitters in the brain: selective neuronal uptake, subcellular localization, and interactions with centrally acting drugs.  Biol Psychiatry. 1970;  2 367-389
• 29 Teufel-Mayer R, Gleitz J. Effects of long-term administration of Hypericum extracts on the affinity and density of the central serotonerigic 5-HT1A and 5-HT2A receptors.  Pharmacopsychiatry. 1997;  30 (Suppl) 113-116
• 30 Thiede H M, Walper A. Inhibition of MAO and COMT by hypericum extracts and hypericin.  J Geriatr Psychiatr Neurol. 1994;  7 (Suppl 1) S 54-S 56